Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian with Antiplatelet Therapy in Healthy Volunteers
NCT03698513Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of milvexian in thrombosis (9 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events (AEs), Incidence of Serious Adverse Events (SAEs) and 5 more. Started Oct 2018; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03698513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698513.